



United States Patent and Trademark Office

DEWIPAT File No. 30.037.10.US

Information Disclosure Statement

Application No.	10/698,894	Attorney Docket	New Docket No. ARC3244R1
Filing Date	10/31/2003	Customer No.	27777
Applicant	Liang C. Dong	Confirmation No.	2950
Examiner		Art Unit	1615
Title	Formulation and Dosage Form Providing Increased Bioavailability of Hydrophobic Drugs		

Applicant submits¹:☒ References listed on the attached form PTO 1449*.☒ Copies of references are enclosed (U.S. patents/applications omitted if filing date is after June 30, 2003).☒ A copy of a communication from a foreign patent office in a counterpart application is enclosed.☐ English language version of foreign search report indicating degree of relevance is enclosed.

☐ Under 35 U.S.C §120, this application relies on the earlier filing date of application serial number _____, filed on _____. The following references were submitted to and/or cited by the Office in the prior application and, therefore, are not provided in this application.

This statement is being filed:

☐ with the application.☐ within three months of the filing date of the application.☒ before the receipt of a first Office Action on the merits.☐ after a first Office Action on the merits, but before receipt of a final Office Action or a Notice of Allowance.

☐ I, the undersigned, hereby certify that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated _____, which is not more than three months prior to filing of this statement.

☐ after a first Office Action on the merits, but before receipt of a final Office Action or a Notice of Allowance.

☐ Late submission fee \$ _____ under 37 CFR 1.17(p) is enclosed.

☐ after a final Office Action or a Notice of Allowance, but before payment of the issue fee. I, the undersigned, hereby certify that each item of information in this statement was cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated _____, which is not more than three months prior to filing this statement. Applicant hereby petitions under CFR 1.97(d) for this statement to be considered.

☐ Submission fee \$ _____ under 37 CFR 1.17(p) is enclosed.

☒ Please apply any additional charges or credits to Deposit Account No. **10-0750**.

SIGNATURE OF Applicant, Attorney, or Agent

Name	Adenike A. Adewuya	Registration No.	42,254
Signature	<i>Adenike Adewuya</i>		
Date	5/4/2004	Telephone	281-477-3450

☒ *Total of 2 form PTO-1449 are submitted.

¹ This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the enclosed documents constitute "prior art." If it should be determined that any of the submitted documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.



United States Patent and Trademark Office		DEWIPAT File No. 30.037.10.US	
Form PTO/AIA 101 (Modified)	Information Disclosure Citation		Sheet 1 of 2
Application No.	10/698,894	Attorney Docket	ARC3244R1
Filing Date	10/31/2003	Customer No.	27777
Applicant	Liang C. Dong	Confirmation No.	2950
Examiner		Art Unit	1615
Title	Formulation and Dosage Form Providing Increased Bioavailability of Hydrophobic Drugs		

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.	Document Number Number-Kind Code	Publication Date mm-dd-yyyy	Applicant/Patentee
	A1	US-2002119198-A1	08-29-2002	GAO, Ping
	A2	US-2003133974-A1	07-17-2003	CURATOLO, William
	A3	US-2003232078-A1	12-18-2003	DONG, Liang
	A4	US-3845770	05-11-1974	THEEUWES, Felix
	A5	US-3916899	04-11-1975	THEEUWES, Felix
	A6	US-4077407	03-07-1978	THEEUWES, Felix
	A7	US-4200098	04-29-1980	AYER, Atul D.
	A8	US-4627850	12-09-1986	DETERS, Joseph C.
	A9	US-4627851	12-09-1986	WONG, Patrick S.L.
	A10	US-4915949	04-10-1990	WONG, Patrick S.L.
	A11	US-4931285	06-05-1990	EDGREN, David E.
	A12	US-5006346	04-09-1991	EDGREN, David E.
	A13	US-5024842	06-18-1991	EDGREN, David E.
	A14	US-5126142	06-30-1992	AYER, Atul D.
	A15	US-5160743	11-03-1992	EDGREN, David E.
	A16	US-5190765	03-02-1993	JAO, Frank
	A17	US-5252338	10-12-1993	JAO, Frank
	A18	US-5324280	06-28-1994	WONG, Patrick S.L.
	A19	US-5413572	05-09-1995	WONG, Patrick S.L.
	A20	US-5578642	11-26-1996	SHALKA, Barry A.
	A21	US-5614578	03-25-1997	DONG, Liang
	A22	US-5620705	04-15-1997	DONG, Liang
	A23	US-5633011	05-27-1997	DONG, Liang
	A24	US-5660861	08-26-1997	JAO, Frank
	A25	US-5965160	10-12-1999	BENITA, Simon
	A26	US-6057289	05-02-2000	MULYE, Nirmal
	A27	US-6174547	01-16-2001	DONG, Liang
	A28	US-6183466	02-06-2001	WONG, Patrick S.L.
	A29	US-6221391	04-24-2001	ROUFFER, Mark T.
	A30	US-6245357	06-12-2001	EDGREN, David E.
	A31	US-6284268	09-04-2001	MISHRA, Awadhesh

EXAMINER: _____ DATE CONSIDERED: _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		United States Patent and Trademark Office		DEWIPAT File No. 30.037.10.US	
Form PTO-1449 (Modified)		Information Disclosure Citation			
		Sheet 2 of 2			
Application No.	10/698,894	Attorney Docket	ARC3244R1		
Filing Date	10/31/2003	Customer No.	27777		
Applicant	Liang C. Dong	Confirmation No.	2950		
Examiner		Art Unit	1615		
Title	Formulation and Dosage Form Providing Increased Bioavailability of Hydrophobic Drugs				

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.	Document Number Number-Kind Code	Publication Date mm-dd-yyyy	Applicant/Patentee
	A32	US-6342249	01-29-2002	WONG, Patrick S.L.
	A33	US-6419952	07-16-2002	WONG, Patrick S.L.
	A34	US-6436430	08-20-2002	MULYE, Nirmal
	A35	US-6551613-B1	04-22-2003	DONG, Liang

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code	Publication Date mm-dd-yyyy	Applicant/Patentee	T
	A36	WO-02/22158-A1	03-21-2002	RPG Life Sciences Limited	

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	A37	PCT International Search Report Dated 04/06/2004	

EXAMINER: _____ DATE CONSIDERED: _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.